The role of interleukin-17 in bone metabolism and inflammatory skeletal diseases
2
조회
0
다운로드
3
인용
0
참고문헌
키워드
초록
The balance between osteoblast-dependent bone formation and osteoclast-dependent bone resorption maintains bone homeostasis. In inflammatory conditions, this balance shifts toward bone resorption, causing osteolytic bone lesions observed in rheumatoid arthritis and periodontitis. A recently discovered family of cytokine IL-17 is widely reported to mediate diverse inflammatory processes. During the last decade, novel roles for IL-17 in skeletal homeostasis have been discovered indicating the potential importance of this cytokine in bone metabolism. This review will summarize and discuss the involvement of IL-17 during bone homeostasis in both physiologic and pathologic conditions. A better understanding of the role of IL-17 in skeletal systems warrants an advance in bone biology, as well as development of therapeutic strategies against bone-lytic diseases, such as rheumatoid arthritis and periodontitis. [BMB Reports 2013; 46(10): 479-483]
Abstract
The balance between osteoblast-dependent bone formation and osteoclast-dependent bone resorption maintains bone homeostasis. In inflammatory conditions, this balance shifts toward bone resorption, causing osteolytic bone lesions observed in rheumatoid arthritis and periodontitis. A recently discovered family of cytokine IL-17 is widely reported to mediate diverse inflammatory processes. During the last decade, novel roles for IL-17 in skeletal homeostasis have been discovered indicating the potential importance of this cytokine in bone metabolism. This review will summarize and discuss the involvement of IL-17 during bone homeostasis in both physiologic and pathologic conditions. A better understanding of the role of IL-17 in skeletal systems warrants an advance in bone biology, as well as development of therapeutic strategies against bone-lytic diseases, such as rheumatoid arthritis and periodontitis. [BMB Reports 2013; 46(10): 479-483]
참고문헌 (48)
- Moseley, T. A., "Interleukin-17 family and IL-17 receptors", Cytokine Growth Factor Rev, 14, pp.155~174 (2003)
- Rouvier, E., "CTLA-8, cloned from an activated T cell, bearing AU-rich messenger RNA instability sequences, and homologous to a herpesvirus saimiri gene", J. Immunol, 150, pp.5445~5456 (1993)
- Witowski, J., "Interleukin- 17: a mediator of inflammatory responses", Cell Mol. Life Sci, 61, pp.567~579 (2004)
- Korn, T., "IL-17 and Th17 Cells", Annu. Rev. Immunol, 27, pp.485~517 (2009)
- Yao, Z., "Herpesvirus Saimiri encodes a new cytokine, IL-17, which binds to a novel cytokine receptor", Immunity, 3, pp.811~821 (1995)
- Kuestner, R. E., "Identification of the IL-17 receptor related molecule IL-17RC as the receptor for IL-17F.", J. Immunol, 179, pp.5462~5473 (2007)
- Toy, D., "Cutting edge: interleukin 17 signals through a heteromeric receptor complex", J. Immunol, 177, pp.36~39 (2006)
- Meng, F., "Interleukin-17 signaling in inflammatory, Kupffer cells, and hepatic stellate cells exacerbates liver fibrosis in mice", Gastroenterology, 143, pp.765~776 (2012)
- Gu, Y., "Interleukin (IL)-17 promotes macrophages to produce IL-8, IL-6 and tumour necrosis factor-alpha in aplastic anaemia", Br. J. Haematol, 142, pp.109~114 (2008)
- Kawanokuchi, J., "Production and functions of IL-17 in microglia", J. Neuroimmunol, 194, pp.54~61 (2008)
- Beklen, A., "MMPs, IL-1, and TNF are regulated by IL-17 in periodontitis", J. Dent. Res, 86, pp.347~351 (2007)
- Jovanovic, D. V., "IL-17 stimulates the production and expression of proinflammatory cytokines, IL-beta and TNF-alpha, by human macrophages", J. Immunol, 160, pp.3513~3521 (1998)
- Mahanonda, R., "Effects of IL-17 on human gingival fibroblasts", J. Dent. Res, 87, pp.267~272 (2008)
- Shahrara, S., "IL-17-mediated monocyte migration occurs partially through CC chemokine ligand 2", monocyte chemoattractant protein-1 induction, 2010, pp.184, 4479~4487
- Barin, J. G., "Macrophages participate in IL-17-mediated inflammation", Eur. J. Immunol, 42, pp.726~736 (2012)
- Hosokawa, Y., "Catechins inhibit CCL20 production in IL-17A-stimulated human gingival fibroblasts", Cell. Physiol. Biochem, 24, pp.391~396 (2009)
- Zhang, F., "Interleukin-17A induces cathepsin K and MMP-9 expression in osteoclasts via celecoxib-blocked prostaglandin E2 in osteoblasts", Biochimie, 93, pp.296~305 (2011)
- Zhang, F., "IL-17A stimulates the expression of inflammatory cytokines via celecoxib-blocked prostaglandin in MC3T3- E1 cells", Arch. Oral Biol, 55, pp.679~688 (2010)
- Van Bezooijen, R. L., "Effect of interleukin-17 on nitric oxide production and osteoclastic bone resorption: is there dependency on nuclear factor-kappaB and receptor activator of nuclear factor kappaB (RANK)", RANK ligand signaling?, 2001, pp.28, 378~386
- Trajkovic, V., "Interleukin-17 stimulates inducible nitric oxide synthase activation in rodent astrocytes", J. Neuroimmunol, 119, pp.183~191 (2001)
- Kotake, S., "IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis", J. Clin. Invest, 103, pp.1345~1352 (1999)
- Van bezooijen, R. L., "Interleukin-17: A new bone acting cytokine in vitro", J. Bone Miner. Res, 14, pp.1513~1521 (1999)
- Sato, K., "Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction", J. Exp. Med, 203, pp.2673~2682 (2006)
- Yago, T., "IL-17 induces osteoclastogenesis from human monocytes alone in the absence of osteoblasts, which is potently inhibited by anti- TNF-alpha antibody: a novel mechanism of osteoclastogenesis by IL-17", J. Cell Biochem, 108, pp.947~955 (2009)
- Kitami, S., "IL-17A suppresses the expression of bone resorption-related proteinases and osteoclast differentiation via IL-17RA or IL-17RC receptors in RAW264. 7 cells", Biochimie, 92, pp.398~404 (2010)
- Balani, D., "Interleukin-17A stimulates granulocyte-macrophage colony-stimulating factor release by murine osteoblasts in the presence of 1,25-dihydroxyvitamin D(3) and inhibits murine osteoclast development in vitro", Arthritis Rheum, 65, pp.436~446 (2013)
- Huang, W., "Interleukin-17A : a T-cell-derived growth factor for murine and human mesenchymal stem cells", Stem Cells (Dayton, Ohio), 24, pp.1512~1518 (2006)
- Huang, H., "IL-17 stimulates the proliferation and differentiation of human mesenchymal stem cells: implications for bone remodeling", Cell. Death. Differ, 16, pp.1332~1343 (2009)
- Nam, D., "T-lymphocytes enable osteoblast maturation via IL-17F during the early phase of fracture repair", PloS One, 7, pp.e40044~ (2012)
- Kocic, J., "Interleukin 17 inhibits myogenic and promotes osteogenic differentiation of C2C12 myoblasts by activating ERK1,2", Biochim. Biophys. Acta, 1823, pp.838~849 (2012)
- Ahmed, M, "IL-17 in obesity and adipogenesis", Cytokine. Growth Factor Rev, 21, pp.449~453 (2010)
- Lubberts, E., "Treatment with a neutralizing anti-murine interleukin-17 antibody after the onset of collagen-induced arthritis reduces joint inflammation, cartilage destruction, and bone erosion", Arthritis Rheum, 50, pp.650~659 (2004)
- Koenders, M. I., "Blocking of interleukin-17 during reactivation of experimental arthritis prevents joint inflammation and bone erosion by decreasing RANKL and interleukin-1", Am. J. Pathol, 167, pp.141~149 (2005)
- Koenders, M. I., "Interleukin-17 receptor deficiency results in impaired synovial expression of interleukin-1 and matrix metalloproteinases 3, 9, and 13 and prevents cartilage destruction during chronic reactivated streptococcal cell wall-induced arthritis", Arthritis Rheum, 52, pp.3239~3247 (2005)
- Genovese, M. C., "LY2439821, a humanized anti-interleukin-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: A phase I randomized, double-blind, placebo- controlled, proof-of-concept study", Arthritis Rheum, 62, pp.929~939 (2010)
- Koenders, M. I., "T cell lessons from the rheumatoid arthritis synovium SCID mouse model: CD3-rich synovium lacks response to CTLA-4Ig but is successfully treated by interleukin-17 neutralization", Arthritis Rheum, 64, pp.1762~1770 (2012)
- Zwerina, K., "Anti IL-17A therapy inhibits bone loss in TNF-alpha-mediated murine arthritis by modulation of the T-cell balance", Eur. J. Immunol, 42, pp.413~423 (2012)
- Chao, C. C., "Anti-IL-17A therapy protects against bone erosion in experimental models of rheumatoid arthritis", Autoimmunity, 44, pp.243~252 (2011)
- Lubberts, E., "IL-17 promotes bone erosion in murine collagen-induced arthritis through loss of the receptor activator of NF-kappa B ligand", osteoprotegerin balance, 2003, pp.170, 2655~2662
- Kikuta, J., "Dynamic visualization of RANKL and Th17-mediated osteoclast function", J. Clin. Invest, 123, pp.866~873 (2013)
- Bartold, P. M., "Mechanisms and control of pathologic bone loss in periodontitis", Periodontology, 2000(53), pp.55~69 (2010)
- Oda, T., "Porphyromonas gingivalis antigen preferentially stimulates T cells to express IL-17 but not receptor activator of NF-kappaB ligand in vitro", Oral Microbiol. Immunol, 18, pp.30~36 (2003)
- Takahashi, K., "The potential role of interleukin-17 in the immunopathology of periodontal disease", J. Clin. Periodentol, 32, pp.369~374 (2005)
- Vernal, R., "Levels of interleukin- 17 in gingival crevicular fluid and in supernatants of cellular cultures of gingival tissue from patients with chronic periodontitis", J. Clin. Periodontol, 32, pp.383~389 (2005)
- Yu, J. J., "An essential role for IL-17 in preventing pathogen-initiated bone destruction: recruitment of neutrophils to inflamed bone requires IL-17 receptor-dependent signals", Blood, 109, pp.3794~3802 (2007)
- Schenkein, H. A., "IL-17 in sera from patients with aggressive periodontitis", J. Dent. Res, 89, pp.943~947 (2010)
- Duarte, P. M., "Serum levels of cytokines in subjects with generalized chronic and aggressive periodontitis before and after non-surgical periodontal therapy: a pilot study", J. Periodontol, 81, pp.1056~1063 (2010)
- Adibrad, M., "Signs of the presence of Th17 cells in chronic periodontal disease", J. Periodontal Res, 47, pp.525~531 (2012)
